Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
NCT05822609 on ClinicalTrials.gov · last registry update 2026-06-02
Recruiting now, toward 60 participants. Due to report June 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: Change in urine albumin excretion. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 5 April 2024 — 2 years so far. semaglutide is approved in the US, but not for diabetic kidney disease and type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- University of Washington
- Sponsor type
- Other
- Enrollment
- 60
- Started
- 2024-04-05
- Primary completion
- 2027-06 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in urine albumin excretion
Conditions studied
Diabetic Kidney Disease · Type 1 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.